RxDoctor Payments DataLook up a doctor →

Hector Payan, MD

Critical Care Medicine · El Paso, TXNPI 1093911091

Payments from drug & device makers

$245,352in general payments, 2019–2025

Across 573 payments — averaging $428.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$210K
  • Mylan Specialty L.p.$23K
  • Intuitive Surgical$4K
  • AstraZeneca$3K
  • Viiv Healthcare Company$2K
  • Boehringer Ingelheim$909
  • plus $3K from 25 others

What the payments were for

  • Consulting fees$8,8214%
  • Speaking & faculty fees$217,53489%
  • Travel & lodging$4,3532%
  • Food & beverage$11,5225%
  • Education$3,1051%
  • Gifts$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$245,352 in reported general payments places this provider in the 95th percentile of 507 critical care medicine providers in Texas.

See all critical care medicine providers in Texas

Medicare billing

Part B allowed, 2024
$155,693
Medicare patients
359
Services billed
2,073

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter243$227,434
NucalaMepolizumab24$98,670
XolairOmalizumab25$40,967
Breo ElliptaFluticasone/Vilanterol60$30,847
Breztri AerosphereBudesonide/Glycopyr/Formoterol35$25,971
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr39$20,701
Ambrisentan16$20,244
Spiriva RespimatTiotropium Bromide16$17,427
SymbicortBudesonide/Formoterol Fumarate51$14,668
EliquisApixaban13$10,204
Incruse ElliptaUmeclidinium Bromide12$6,944
Albuterol Sulfate HfaAlbuterol Sulfate282$6,772
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$2,550
Wixela InhubFluticasone Propion/Salmeterol31$2,244
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$2,023

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$209,584$384,595378 claims
AstraZenecaBreztri Aerosphere, Symbicort$2,984$40,63986 claims
Boehringer IngelheimSpiriva Respimat$909$17,42716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 507 critical care medicine providers in Texas.

Other critical care medicine in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →